AI Article Synopsis
Article Abstract
We conducted a randomized multinational study to determine whether 48 weeks of re-treatment with peginterferon-alpha-2a (40 kDa) plus ribavirin would induce a sustained virological response (SVR) in relapsed chronic hepatitis C patients. Patients who had previously relapsed during 24 weeks of untreated follow-up, after having achieved an end-of-treatment virological response with 24 weeks of peginterferon-alpha-2a (40 kDa)/ribavirin combination therapy, within a phase III trial, were studied. Although the recommended dosage was the same as that used at the end of the initial trial, adjustments were permitted. Data on serious adverse events, or adverse events that resulted in dose reductions or discontinuations, were collected. Following re-treatment, the overall SVR rate in the 64 patients was 55%. The SVR rates in patients infected with hepatitis C virus (HCV) genotype 1 and non-1 genotypes were 51% and 63%, respectively. Early (week 12) virological responses were seen in 39 patients (61%) and were predictive of an SVR. Re-treatment was well tolerated. The most frequent adverse events recorded were fatigue (5%) and abdominal pain (3%). Dosages of peginterferon-alpha-2a (40 kDa) and/or ribavirin were modified because of adverse events in 3% and 13% of patients, and because of laboratory abnormalities in 23% and 5% of patients, respectively. Thus, a 48-week course of peginterferon-alpha-2a (40 kDa) plus ribavirin induces an SVR in 55% of patients who relapsed during follow-up after 24 weeks of combination therapy. Physicians should not hesitate to offer re-treatment to patients who relapse after an initial, 24-week course of combination therapy, or who have prematurely stopped treatment because, for example, of laboratory abnormalities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2893.2006.00727.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
Eur J Gastroenterol Hepatol
April 2014
aDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, University of Palermo, Palermo bDepartment of Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples cDepartment of Gastroenterology and Hepatology, University of Torino, Torino dSPARC Consulting, Milan eRoche SpA, Monza fDepartment of Medicine, Centre for Liver Disease, Fatebenefratelli Hospital, Napoli, Italy.
Background: This large prospective multicentre cohort study aimed to improve knowledge of therapy for chronic hepatitis C (CHC) in real clinical practice.
Methods: A diverse population of adults with CHC including patients with comorbid conditions, laboratory abnormalities and demographic features [comorbidities or special populations (CSP)] who were under-represented or excluded from peginterferon registration studies was treated with peginterferon α-2a (40 kDa) or α-2b (12 kDa) plus ribavirin at the investigator's discretion.
Results: During the study, 5399 treatment-naive patients [2527 (46.
Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
Eur J Gastroenterol Hepatol
April 2013
Section of Gastroenterology, Department of Medicine, King Faisal Specialist Hospital and Research Centre KFSH&RC, Riyadh 11211, Saudi Arabia.
Introduction: The role of serum interferon-γ-inducible protein-10 kDa (IP-10) level in the treatment of chronic hepatitis C genotype-4 (HCV-4) and its various subtypes remains unknown. We aimed to study the impact of pretreatment IP-10 levels on the sustained viral response (SVR) in HCV-4 patients (n=64) undergoing peginterferon α-2a/ribavirin therapy.
Patients And Methods: Pretreatment IP-10 levels and HCV-4 subtypes (4a=48.
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
J Clin Gastroenterol
October 2013
*Hôpital Beaujon, Boulevard du Général Leclerc, Clichy, France †Instituto Di Clinica Medica Policlinico, Palermo ∥Department of Clinical Medicine, University of Bologna, Bologna, BO, Italy ‡Internal Medicine Department, Hepatology Division, Gaffrèe e Güinle University Hospital, College of Medicine & Surgery, University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil §Department of Internal Medicine, Saint Louis University School of Medicine, St Louis ¶Kansas City Gastroenterology and Hepatology, LLC, Kansas City, MO #Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA **Hospital La Paz de Madrid, Madrid, Spain ††Interdisziplinäres Facharztzentrum Sachsenhausen, MVZ-Sachsenhausen, Frankfurt ‡‡IST GmbH, Mannheim, Germany §§Roche Products Ltd, Welwyn, UK ∥∥F. Hoffmann-La Roche Ltd, Basel, Switzerland ¶¶Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL.
Goals: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa).
Background: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA <50 IU/mL at treatment week 12, was an important predictor of SVR.
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
J Clin Gastroenterol
March 2013
Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA.
Background And Goal: Patients infected with hepatitis C virus (HCV) with elevated low-density lipoprotein (LDL) levels achieve higher sustained virologic response (SVR) rates after peginterferon (PegIFN)/ribavirin treatment versus patients with lower LDL. Our aim was to determine whether SVR rates in patients with low/elevated LDL can be improved by dose intensification.
Study: In PROGRESS, genotype 1 patients with baseline HCV RNA ≥ 400,000 IU/mL and body weight ≥ 85 kg were randomized to 48 weeks of 180 µg/wk PegIFN α-2a (40 kDa) plus ribavirin (A: 1200 mg/d; B: 1400/1600 mg/d) or 12 weeks of 360 µg/wk PegIFN α-2a followed by 36 weeks of 180 µg/wk, plus ribavirin (C: 1200 mg/d; D: 1400/1600 mg/d).
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Drugs
April 2010
Queen Mary University of London, The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and The London School of Medicine, The Royal London Hospital, London, UK.
Chronic infection with hepatitis C virus (HCV) is a major healthcare problem, affecting an estimated 170 million people worldwide. Interferon-alpha has formed the basis of treatment regimens since the identification of HCV, either alone or in conjunction with the nucleoside analogue ribavirin. The relatively recent introduction of pegylated forms of interferon-alpha, with greater stability and in vivo activity, has substantially improved sustained virological response (SVR) rates compared with unmodified interferon-alpha, with SVR rates of 35-66% when used in conjunction with ribavirin in randomized controlled trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!